Member Publications

Members of the NASH Roundtable contribute important research to the public domain through peer-reviewed articles in medical journals. Below is a selection of recent research co-authored by Roundtable members. For a comprehensive search of NASH-related research by Roundtable members and others, visit pubmed.gov.

A global view of the interplay between non-alcoholic fatty liver disease and diabetes.

Stefan N, Cusi K. Lancet Diabetes Endocrinol. 2022 Apr;10(4):284-296. doi: 10.1016/S2213-8587(22)00003-1.

View Publication »

Impaired Hepatic Mitochondrial Capacity in Nonalcoholic Steatohepatitis Associated With Type 2 Diabetes.

Gancheva S, Kahl S, Pesta D, Mastrototaro L, Dewidar B, Strassburger K, Sabah E, Esposito I, Weiß J, Sarabhai T, Wolkersdorfer M, Fleming T, Nawroth P, Zimmermann M, Reichert AS, Schlensak M, Roden M. Diabetes Care. 2022 Apr 1;45(4):928-937. doi: 10.2337/dc21-1758.

View Publication »

Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study.

Huang DQ, Fowler KJ, Liau J, Cunha GM, Louie AL, An JY, Bettencourt R, Jung J, Gitto Z, Hernandez C, Lopez SJ, Gupta H, Sirlin CB, Marks RM, Loomba R. Aliment Pharmacol Ther. 2022 Apr;55(7):820-827. doi: 10.1111/apt.16844.

View Publication »

Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease.

Tamaki N, Kurosaki M, Huang DQ, Loomba R. Hepatol Res. 2022 Mar 30. doi: 10.1111/hepr.13764.

View Publication »

Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD.

Jung J, Han A, Madamba E, Bettencourt R, Loomba RR, Boehringer AS, Andre MP, Erdman JW Jr, O’Brien WD Jr, Fowler KJ, Sirlin CB, Loomba R. Radiology. 2022 Mar 29:211131. doi: 10.1148/radiol.211131.

View Publication »

Risk of liver-related events by age and diabetes duration in diabetic patients with non-alcoholic fatty liver disease.

Zhang X, Wong GL, Yip TC, Cheung JTK, Tse YK, Hui VW, Lin H, Lai JC, Chan HL, Kong AP, Wong VW. Hepatology. 2022 Mar 25. doi: 10.1002/hep.32476.

View Publication »

Reliability of Histologic Assessment for NAFLD and Development of an Expanded NAFLD Activity Score.

Pai RK, Jairath V, Hogan M, Zou G, Adeyi OA, Anstee QM, Aqel BA, Behling C, Carey EJ, Clouston AD, Corey K, Feagan BG, Kleiner DE, Ma C, McFarlane SC, Noureddin M, Ratziu V, Valasek MA, Younossi ZM, Harrison SA, Loomba R. Hepatology. 2022 Mar 25. doi: 10.1002/hep.32475.

View Publication »

A Simple Test to Identify the Risk of NASH and Cirrhosis in People with Obesity or Diabetes: The Time to Screen is Now.

Cusi K. J Clin Endocrinol Metab. 2022 Mar 25:dgac186. doi: 10.1210/clinem/dgac186.

View Publication »

Non-Alcoholic fatty liver disease-associated DNA methylation and gene expression alterations in the livers of Collaborative Cross mice fed an obesogenic high-fat and high-sucrose diet.

Cusi K. J Clin Endocrinol Metab. 2022 Mar 25:dgac186. doi: 10.1210/clinem/dgac186.

View Publication »

Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.

Ampuero J, Gallego-Durán R, Maya-Miles D, Montero R, Gato S, Rojas Á, Gil A, Muñoz R, Romero-Gómez M. J Gastroenterol. 2022 Mar 24. doi: 10.1007/s00535-022-01860-0.

View Publication »

Is lean non-alcoholic fatty liver disease a distinct entity?

Lin H, Wong VW. Hepatol Int. 2022 Mar 24. doi: 10.1007/s12072-022-10324-9.

View Publication »

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.

Harrison SA, Abdelmalek MF, Neff G, Gunn N, Guy CD, Alkhouri N, Bashir MR, Freilich B, Kohli A, Khazanchi A, Sheikh MY, Leibowitz M, Rinella ME, Siddiqui MS, Kipnes M, Moussa SE, Younes ZH, Bansal M, Baum SJ, Borg B, Ruane PJ, Thuluvath PJ, Gottwald M, Khan M, Chen C, Melchor-Khan L, Chang W, DePaoli AM, Ling L, Lieu HD. Lancet Gastroenterol Hepatol. 2022 Mar 21:S2468-1253(22)00017-6. doi: 10.1016/S2468-1253(22)00017-6.

View Publication »

Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).

Brandman D, Boyle M, McPherson S, Van Natta ML, Sanyal AJ, Kowdley K, Neuschwander-Tetri B, Chalasani N, Abdelmalek MF, Terrault NA, McCullough A, Bettencourt R, Caussy C, Kleiner DE, Behling C, Tonascia J, Anstee QM, Loomba R; Members of the Nonalcoholic Steatohepatitis Clinical Research Network. Aliment Pharmacol Ther. 2022 Mar 17. doi: 10.1111/apt.16874.

View Publication »

Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

Deckmyn O, Poynard T, Bedossa P, Paradis V, Peta V, Pais R, Ratziu V, Thabut D, Brzustowski A, Gautier JF, Cacoub P, Valla D. Biomedicines. 2022 Mar 17;10(3):699. doi: 10.3390/biomedicines10030699.

View Publication »

Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis.

Ng CH, Muthiah MD, Xiao J, Chin YH, Lim G, Lim WH, Tay P, Tan DJH, Yong JN, Pan XH, Koh JWH, Chew N, Syn N, Tan E, Huang DQ, Siddiqui MS, Loomba R, Sanyal AJ, Noureddin M. Aliment Pharmacol Ther. 2022 Mar 14. doi: 10.1111/apt.16808.

View Publication »

Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.

Zamani M, Alizadeh-Tabari S, Singh S, Loomba R. Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16879.

View Publication »

Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease.

Castillo-Leon E, Morris HL, Schoen C, Bilhartz J, McKiernan P, Miloh T, Palle S, Kabbany MN, Munoz B, Mospan AR, Rudolph B, Xanthakos SA, Vos MB, Target-Nash Investigators. Children (Basel). 2022 Mar 8;9(3):374. doi: 10.3390/children9030374.

View Publication »

Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.

Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Lancet Oncol. 2022 Mar 4:S1470-2045(22)00078-X. doi: 10.1016/S1470-2045(22)00078-X.

View Publication »

A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease.

Pennisi G, Pipitone RM, Cabibi D, Enea M, Romero-Gomez M, Viganò M, Bugianesi E, Wong VW, Fracanzani AL, Sebastiani G, Berzigotti A, Di Salvo F, Giannone AG, La Mantia C, Lupo G, Porcasi R, Vernuccio F, Zito R, Di Marco V, Cammà C, Craxì A, de Ledinghen V, Grimaudo S, Petta S. Liver Int. 2022 Mar 4. doi: 10.1111/liv.15232.

View Publication »

Global multi-stakeholder endorsement of the MAFLD definition.

Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2022 Mar 3:S2468-1253(22)00062-0. doi: 10.1016/S2468-1253(22)00062-0.

View Publication »

NAFLD increases Risk of Carotid Atherosclerosis and Ischemic Stroke. An Updated Meta-Analysis with 135,602 Individuals.

Tang ASP, Chan KE, Quek J, Xiao J, Tay P, Teng M, Lee KS, Lin SY, Myint MZ, Tan B, Sharma VK, Tan DJH, Lim WH, Kaewdech A, Huang D, Chew NW, Siddiqui MS, Sanyal AJ, Muthiah M, Ng CH. Clin Mol Hepatol. 2022 Mar 2. doi: 10.3350/cmh.2021.0406.

View Publication »

Association of Obesity, Diabetes, and Alcohol Use With Liver Fibrosis Among US Adults With Hepatitis C Virus Infection.

Migdal AL, Jagannathan R, Qayed E, Cusi K, McCoy RG, Pasquel FJ, Miller LS. JAMA Netw Open. 2022 Mar 1;5(3):e2142282. doi: 10.1001/jamanetworkopen.2021.42282.

View Publication »

Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation.

Gallego-Durán R, Ampuero J, Pastor-Ramírez H, Álvarez-Amor L, Del Campo JA, Maya-Miles D, Montero-Vallejo R, Cárdenas-García A, Pareja MJ, Gato-Zambrano S, Millán R, Del Carmen Rico M, Luque-Sierra A, Gil-Gómez A, Rojas Á, Muñoz-Hernández R, García-Lozano M, Aller R, Andrade RJ, García-Monzón C, Andreola F, Martín F, Jalan R, Romero-Gómez M. Sci Rep. 2022 Mar 1;12(1):3418. doi: 10.1038/s41598-022-06614-9.

View Publication »

Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project.

Sanyal AJ, Shankar SS, Calle RA, Samir AE, Sirlin CB, Sherlock SP, Loomba R, Fowler KJ, Dehn CA, Heymann H, Kamphaus TN. Nat Med. 2022 Mar;28(3):430-432. doi: 10.1038/s41591-021-01652-8.

View Publication »

Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients.

Stepanova M, Kabbara K, Mohess D, Verma M, Roche-Green A, AlQahtani S, Ong J, Burra P, Younossi ZM. Hepatol Commun. 2022 Feb 28. doi: 10.1002/hep4.1915.

View Publication »

Read More »

Follow us on LinkedIn for publication updates